First patients to receive new 'T-Cell Redirecting' drug for rare blood cancers

NCT ID NCT06150157

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called JNJ-88549968 for blood cancers with a specific genetic change (CALR mutation). The main goals are to find a safe dose and understand how the body handles the drug. The drug works by guiding a patient's own immune cells to attack the cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CH LYON SUD - Hematology
RECRUITING

Pierre-Bénite, 69495, France
Carmel Medical Center
RECRUITING

Haifa, 3436212, Israel
Charite Campus Benjamin Franklin
RECRUITING

Berlin, 12203, Germany
Churchill Hospital
RECRUITING

Oxford, OX3 7LE, United Kingdom
City of Hope
RECRUITING

Duarte, California, 91010, United States
Guy's and St Thomas' Hospital
RECRUITING

London, SE1 9RT, United Kingdom
Hadassah University Hospita Ein Kerem
RECRUITING

Jerusalem, 9112001, Israel
Hopital Saint Louis
RECRUITING

Paris, 75475, France
Hosp. Clinico Univ. de Valencia
RECRUITING

Valencia, 46010, Spain
Hosp. Univ. Germans Trias I Pujol
RECRUITING

Badalona, 08916, Spain
Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Med. Universitatsklinik Essen
RECRUITING

Essen, 45147, Germany
Medizinische Hochschule Hannover
RECRUITING

Hanover, 30625, Germany
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffit Cancer center
RECRUITING

Tampa, Florida, 33612, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States
Policlinico Sant'Orsola Malpighi
RECRUITING

Bologna, 40138, Italy
Policlinico di Milano
RECRUITING

Milan, 21022, Italy
Princess Margaret Cancer Centre University Health Network
RECRUITING

Toronto, Ontario, M5G 1Z5, Canada
Sarah Cannon Cancer Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sheba Medical Center
RECRUITING

Ramat Gan, 5266202, Israel
Tel Aviv Sourasky Medical Center
RECRUITING

Tel Aviv, 64239, Israel
UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center
RECRUITING

Aurora, Colorado, 80045, United States
Universitaetsklinikum Heidelberg
RECRUITING

Heidelberg, 69120, Germany
Universitaetsklinikum Regensburg
RECRUITING

Regensburg, 93053, Germany
Universitaetsklinikum der RWTH Aachen
RECRUITING

Aachen, 52074, Germany
University College London Hospitals Nhs Foundation Trust
RECRUITING

London, NW1 2PG, United Kingdom
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS MYELOPROLIFERATIVE DISORDERS NEOPLASMS